Accelerate Diagnostics reports Q4 EPS (38c)

Reports Q4 revenue $2.8M vs. $3M last year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year. Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in gross margin primarily resulted from higher manufacturing related costs due to inflation and other factors. Ended the quarter with approximately $16.3M in cash and cash equivalents, compared to $20.9M at the start of the fourth quarter, a reduction in cash and cash equivalents for the fourth quarter of 2024 of $4.6M.